New SPR study results about inhibitory antibodies of FVIII published

A new article describing the interaction between inhibitory antibodies against the essential blood clotting protein FVIII from a severe haemophilia A patient and FVIII from therapeutic concentrates of different sources has been published by Biaffin GmbH & Co KG and coauthors.  The study was designed to reveal the differences in the kinetics of recombinant and plasma-derived FVIII concentrates with inhibitory antibodies and the role of von Willebrand factor (VWF) in complex with FVIII with regard to immunogenicity. Please read more about these new SPR study results published in the international Journal Haemophilia: onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2012.02858.x/pdf